Header Logo

Connection

Theodore Pincus to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Theodore Pincus has written about Treatment Outcome.
Theodore Pincus
Connection Strength
1.175
Treatment Outcome
  1. Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. J Rheumatol. 2019 01; 46(1):27-30.
    View in: PubMed
    Score: 0.085
  2. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S82-93.
    View in: PubMed
    Score: 0.069
  3. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015; 22(1-2):46-50.
    View in: PubMed
    Score: 0.064
  4. The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015; 22(1-2):89-103.
    View in: PubMed
    Score: 0.064
  5. Assessing remission in rheumatoid arthritis on the basis of patient reported outcomes--advantages of using RAPID3/MDHAQ in routine care. Bull Hosp Jt Dis (2013). 2014; 72(2):136-41.
    View in: PubMed
    Score: 0.061
  6. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3.
    View in: PubMed
    Score: 0.060
  7. Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013 May; 65(5):729-36.
    View in: PubMed
    Score: 0.058
  8. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol. 2013 Apr; 40(4):386-93.
    View in: PubMed
    Score: 0.057
  9. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(2):117-20.
    View in: PubMed
    Score: 0.057
  10. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
    View in: PubMed
    Score: 0.057
  11. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
    View in: PubMed
    Score: 0.057
  12. Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). Bull NYU Hosp Jt Dis. 2012; 70 Suppl 1:14-20.
    View in: PubMed
    Score: 0.053
  13. Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care. Bull NYU Hosp Jt Dis. 2011; 69(2):104-10.
    View in: PubMed
    Score: 0.049
  14. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2010 Sep; 49(9):1795-6; author reply 1796-7.
    View in: PubMed
    Score: 0.047
  15. Quantitative clinical rheumatology: "keep it simple, stupid": MDHAQ function, pain, global, and RAPID3 quantitative scores to improve and document the quality of rheumatologic care. J Rheumatol. 2009 Jun; 36(6):1099-100.
    View in: PubMed
    Score: 0.044
  16. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol. 2008 Apr; 35(4):603-9.
    View in: PubMed
    Score: 0.040
  17. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008; 66(3):216-23.
    View in: PubMed
    Score: 0.040
  18. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
    View in: PubMed
    Score: 0.037
  19. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
    View in: PubMed
    Score: 0.037
  20. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005 Apr; 52(4):1031-6.
    View in: PubMed
    Score: 0.033
  21. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?. Ann Intern Med. 2002 Jan 01; 136(1):76-8.
    View in: PubMed
    Score: 0.026
  22. Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018 08; 70(8):1198-1205.
    View in: PubMed
    Score: 0.021
  23. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford). 2013 Oct; 52(10):1890-7.
    View in: PubMed
    Score: 0.015
  24. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
    View in: PubMed
    Score: 0.012
  25. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
    View in: PubMed
    Score: 0.012
  26. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009; 11(1):R7.
    View in: PubMed
    Score: 0.011
  27. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008 Sep; 58(9):2642-51.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.